Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Brandon J. DeKosky"'
Autor:
Bharat Madan, Eswar R. Reddem, Pengfei Wang, Ryan G. Casner, Manoj S. Nair, Yaoxing Huang, Ahmed S. Fahad, Matheus Oliveira Souza, Bailey B. Banach, Sheila N. López Acevedo, Xiaoli Pan, Rajani Nimrania, I‐Ting Teng, Fabiana Bahna, Tongqing Zhou, Baoshan Zhang, Michael T. Yin, David D. Ho, Peter D. Kwong, Lawrence Shapiro, Brandon J. DeKosky
Publikováno v:
Aiche Journal. American Institute of Chemical Engineers
Antiviral monoclonal antibody (mAb) discovery enables the development of antibody-based antiviral therapeutics. Traditional antiviral mAb discovery relies on affinity between antibody and a viral antigen to discover potent neutralizing antibodies, bu
Autor:
Brian M. Petersen, Sophia A. Ulmer, Emily R. Rhodes, Matias F. Gutierrez-Gonzalez, Brandon J. Dekosky, Kayla G. Sprenger, Timothy A. Whitehead
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
Monoclonal antibodies (mAbs) are an important class of therapeutics used to treat cancer, inflammation, and infectious diseases. Identifying highly developable mAb sequences in silico could greatly reduce the time and cost required for therapeutic mA
Autor:
Emily R. Rhodes, B. M. Petersen, S. A. Ulmer, Timothy A. Whitehead, M. F. Gutierrez Gonzalez, Kayla G. Sprenger, Brandon J. DeKosky
Monoclonal antibodies (mAbs) are an important class of therapeutics used to treat cancer, inflammation, and infectious diseases. Identifying highly developable mAb sequences in silico could greatly reduce the time and cost required for therapeutic mA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c81b95a547e83d3df014929a20d0ff7
https://doi.org/10.1101/2021.06.22.449488
https://doi.org/10.1101/2021.06.22.449488
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
Monoclonal antibodies (mAbs) are a crucial asset for human health and modern medicine, however, the repeated administration of mAbs can be highly immunogenic. Drug immunogenicity manifests in the generation of anti-drug antibodies (ADAs), and some mA
Autor:
Gabriele Cerutti, Yaroslav Tsybovsky, Bharat Madan, Bailey B. Banach, Matheus Oliveira de Souza, Adam S. Olia, Tongqing Zhou, I-Ting Teng, Yaoxing Huang, Jacy R. Wolfe, Phinikoula S. Katsamba, Peter D. Kwong, Pengfei Wang, Manoj S. Nair, Timothy A. Whitehead, Chen-Hsiang Shen, Ahmed S. Fahad, David D. Ho, Kwok-Yung Yuen, Irene M. Francino-Urdaniz, Brandon J. DeKosky, Jude Bimela, Lihong Liu, Eswar R. Reddem, Amy D. Laflin, Xiaoli Pan, Rajani Nimrania, Lawrence Shapiro, Jian Yu, Alexandra Nazzari, Sheila N. Lopez Acevedo, Paul J. Steiner, Matias Gutiérrez-González, Yang Luo
Publikováno v:
Cell Reports
bioRxiv
Cell Reports, Vol 37, Iss 1, Pp 109771-(2021)
bioRxiv
Cell Reports, Vol 37, Iss 1, Pp 109771-(2021)
Understanding mechanisms of protective antibody recognition can inform vaccine and therapeutic strategies against SARS-CoV-2. We report a monoclonal antibody, 910-30, targeting the SARS-CoV-2 receptor-binding site for ACE2 as a member of a public ant
Autor:
Bo Wang, Christien A. Kluwe, Oana I. Lungu, Brandon J. DeKosky, Scott A. Kerr, Erik L. Johnson, Hidetaka Tanno, Chang-Han Lee, Jiwon Jung, Alec B. Rezigh, Sean M. Carroll, Ann N. Reyes, Janelle R. Bentz, Itamar Villanueva, Amy L. Altman, Robert A. Davey, Andrew D. Ellington, George Georgiou
Publikováno v:
Scientific Reports
The ongoing evolution of Ebolaviruses poses significant challenges to the development of immunodiagnostics for detecting emergent viral variants. There is a critical need for the discovery of monoclonal antibodies with distinct affinities and specifi